Breadcrumb AMCP.org Resource Center Topics View All AMCP joins 10 other stakeholders in letter to FDA advocating for the removal of the biosimilarity statement on labeling for biosimilar products. 3/18/19 AMCP joins 10 other stakeholders in letter to FDA advocating for the removal of the biosimilarity statement on labeling for biosimilar products. Biosimilars Labeling Group Letter 6-1.pdf